H19 is an imprinted and developmentally regulated gene whose product remains apparently untranslated. In a previous study on breast adenocarcinomas, we reported that overexpression of the H19 gene was signi®cantly correlated with the presence of steroid receptors, suggesting the putative role of hormones in H19 transcription. To determine the mode of steroid action, we have detected levels of H19 RNA synthesis during mammary gland development by in situ hybridization (ISH): two peaks of H19 transcription occur during puberty and pregnancy. Furthermore, we demonstrated by ISH that in the uterus H19 RNA synthesis is high during estrus and metestrus phases. To test steroid control of H19 transcription, ovariectomized and adrenalectomized mice were supplemented, 1 week after surgery, with 17-b-estradiol (E2, 20 mg/kg/day), progesterone (P, 1 mg/kg/day) or corticosterone (B, 0.3 mg/ kg/day) for 2 weeks. According to ISH data, E2 and to a lesser extent B stimulated H19 transcription in the uterus, whereas P inhibited it. To con®rm the in vivo results, in vitro experiments were performed using cultures of MCF-7 cells (a hormone-sensitive mammary cell line). E2 stimulated the endogenous H19 gene of this cell line and tamoxifen inhibited this eect. Furthermore, we performed transient cotransfections in MCF-7, in HBL-100 (another hormone-sensitive mammary cell line) and in BT-20 (a hormone-insensitive mammary cell line) with various constructs of ERa (WT or mutated) and PR-A, in presence or absence of steroid hormones. We demonstrated that ERa up-regulated the H19 promoter in MCF-7 and in HBL-100, whereas PR-A did not have any eect per se. Moreover, in MCF-7, PR-A antagonized clearly the ERa-mediated promoter enhancement, but in HBL-100 this counteracting eect on the ERa up-regulation was not found. Interestingly, the same experiments performed in BT-20 cell line provided very similar results as those obtained in MCF-7 cells, with a clear down-regulation mediated by PR-A on the H19 promoter. All these in vitro data are in agreement with in vivo results. In addition, data obtained with ERa mutants indicate that H19 promoter activation is both ligand-dependent and ligand-independent. We have thus demonstrated that H19 gene expression is controlled by steroid hormones; furthermore, this gene is highly expressed in hormone-sensitive organs when the hormonal stimulation is accompanied with a morphological repair.
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Introduction
The H19 gene maps to human chromosome 11p15.5 (Glaser et al., 1989) and to the distal part of chromosome 7 in the mouse (Pachnis et al., 1984) . In human and mouse, H19 is located in the vicinity of IGF-2 and the two genes are imprinted (Bartolomei et al., 1991; Zhang and Tycko, 1992) . Although H19 and IGF-2 are contiguous, H19 is exclusively expressed from the maternal allele (Bartolomei et al., 1991) , whereas IGF-2 is only expressed from the paternal allele (De Chiara et al., 1991) . In fact, these two genes share a common set of enhancers and this opposite regulation can be explained by a promoter/enhancer competition (Zemel et al., 1992; Bartolomei et al., 1993; Eversole-Cire et al., 1995; Leighton et al., 1995; Webber et al., 1998) .
The H19 gene codes for a capped, spliced and polyadenylated RNA. A particularity of this product is its apparent inability to be translated when the UTR 5' is not experimentally altered (Brannan et al., 1990; Joubel et al., 1996) . As a consequence, it has been proposed that this gene could act as a`riboregulator' (Brannan et al., 1990) . Recently, Li et al. (1998) proposed that H19 RNA is associated with polysomes and modulates the cytoplasmic level of IGF2 mRNAs.
H19 is expressed in most fetal tissues, except in the thymus, and is repressed in almost all adult organs except the cardiac and skeletal muscles Leibovitch et al., 1991) , the uterus (Ariel et al., 1997b) , to a lesser extent the kidney, the adrenal glands, the lung (Zhang and Tycko, 1992) and the mammary gland, where a basal but signi®cant expression has been detected (Douc-Rasy et al., 1993; Dugimont et al., 1995; Adriaenssens et al., 1998) . This pattern of expression suggests that H19 could be implicated in fetal development. H19 could also intervene in postnatal development when the concerned organ continually undergoes repair, as for instance is the case with the mammary gland or the uterus. In other respects, several authors observed an overexpression or a reexpression of the H19 gene in a wide variety of cancers; thus H19 could also be involved in the pathological processes leading to tumor formation (Douc-Rasy et al., 1993; Cooper et al., 1996; Ariel et al., 1997a) . This overexpression of H19 in tumors may or not be associated with a loss of imprinting, a loss of heterozygosity or both phenomena Kondo and Takahashi, 1996; Wang et al., 1996; Yballe et al., 1996; Van Roozendaal et al., 1998) . In fact, the imprinting status of the H19 gene in tumors seems to depend on the organ considered.
To date, the function of this gene remains largely unestablished. A tumor suppressor role was proposed by Hao et al. (1993) who observed a decrease of tumorigenicity of a cancerous cell line (G401) in which an ectopic H19 gene was overexpressed. Rather indirect results obtained by several groups are in agreement with this tumor suppressor property of H19 (Moulton et al., 1994; Taniguchi et al., 1995; Cui et al., 1997) . In contrast, Biran et al. (1994) and Cooper et al. (1996) considered this gene as a tumoral marker since its overexpression correlated with the tumor progression in urothelial and bladder carcinomas. Furthermore, Lustig-Yariv et al. (1997) denied the hypothesis of H19 as a tumor suppressor gene because the tumorigenicity of choriocarcinoma cell lines was accompanied with a high level of H19 RNA synthesis. Expression of the H19 gene in fetal tissues and its overexpression in tumors derived from these tissues induced Ariel et al. (1997a) to consider the H19 product as an`oncofetal RNA'. However, this notion of`oncofetal RNA' de®nes the pattern of H19 expression rather than bringing any knowledge about the accurate function of the gene. Recently, Li et al. (1998) reexamined a putative role for H19 transcript in humans and their observations were consistent with a H19 antagonist role to IGF2 expression in trans and could represent a ®rst approach to clarify this unsolved issue.
Elsewhere, some authors described an up-regulating action of IGFs, insulin and protein kinase A, or a down-regulating action of growth factors (TNFa, IFNg, TGFb1), serum, protein kinase C on the H19 gene expression in dierent models (Voutilainen et al., 1994; Han et al., 1996) . Nevertheless, up to the recent past, no active factor responsible for the regulation of the H19 promoter has been identi®ed. In this line of evidence, Kopf et al. (1998) recently reported that the human H19 promoter is indirectly activated by retinoic acid. This eect is under the control of both the promoter and a 3' downstream region. In addition, we recently demonstrated that the p53 protein downregulates the H19 promoter and based on this result, it has been proposed that H19 could be implicated in the cell cycle .
We have previously reported that in breast adenocarcinomas, overexpression of H19 is significantly correlated with the presence of estrogen and progesterone receptors . To determine the role of these receptors and their ligands on the H19 gene expression, we studied H19 activity in two healthy steroid hormone-sensitive organs (the mammary gland and the uterus). Indeed, although numerous data have been published about expression modalities of this gene in cancers or cancerous cell lines, little is known about its activity in normal tissues.
The advantage of the mammary gland comes from its physiological properties: it is a unique organ as its development mainly occurs in the adult. Its development depends on three major phenomena: (1) interactions between the epithelium and the underlying mesenchymal tissue (Sakakura, 1991; Cunha et al., 1992) ; (2) hormone and growth factor stimulations (Nandi, 1958; Haslam, 1987; Snedeker et al., 1991; Daniel and Robinson, 1992) ; and (3) regulatory interactions with components of the extracellular matrix (Jones et al., 1991; Thesle et al., 1995) . The fetal development of the mammary gland is not controlled by hormones. On the contrary, its major morphological and functional modi®cations which occur during adulthood are hormone dependent; steroid, corticoid, pituitary and placental hormones are involved (Topper and Freeman, 1980) . Steroid hormones act on the epithelial cells, but also on the adjacent mesenchymal cells. Their action may be direct, provoking a proliferation and/or a dierentiation of the epithelial cells, but it may also be indirect, inducing a production of paracrine growth factors which then stimulate the epithelial cells. These stimulations result in the development of the mammary gland during puberty, estrus cycle, pregnancy and lactation. During the latter, the mammary gland achieves its maximum dierentiation and ensures a nutritive function.
In parallel, steroid hormones control the development and functions of ovaries and the female genital tract throughout the sexual life of the organism. Indeed, the follicular dierentiation in ovaries and the blastocyst implantation which requires a peculiar physiological state of the uterus are regulated by steroid hormones.
Aware of the advantages of the mentioned organs, in the ®rst section of this study, we determined by in situ hybridization (ISH) H19 gene expression during mouse mammary gland development. The observed modulations suggest that steroid hormones are involved in the control of H19 RNA synthesis. To test this hypothesis, in the second section we determined the modulations of H19 gene expression during the normal physiological variations of hormone levels throughout the estrus cycle. In the third section, we determined the role of three steroid hormones (corticosterone, 17-b-estradiol, progesterone) on H19 RNA synthesis in ovariectomized and adrenalectomized mice. Finally, in the last section, we followed an in vitro strategy to con®rm the in vivo results. To this end, we demonstrated the control of the endogenous H19 gene expression by hormones in cultured cells and performed cotransfection experiments by using a reporter gene (luciferase) driven by the minimal H19 promoter and dierent estrogen or progesterone receptor expression vectors (wild-type or mutated sequences). These experiments con®rmed the activity of steroid hormones, via their nuclear receptors, on the H19 promoter.
Results

H19 gene expression during mouse mammary gland development
As a ®rst approach, we studied by ISH the H19 gene expression during mammary gland development. In 14.5-day-old female fetus, we observed a high Steroid hormones modulate H19 gene expression E Adriaenssens et al Figure 1 H19 gene expression during mouse mammary gland development. I: histological coloration. II: Hoechst staining. III: in situ hybridization with an antisense H19 riboprobe. Mammary gland at dierent stages of development: (1) a mammary bud (arrow) of a mouse embryo (E 14.5); (2) mammary cord of a new-born mouse (D0); (3 ± 6) mammary glands of mice before (D25) or during (D35) puberty, during pregnancy, and lactation respectively; (7 and 8) mammary gland during involution, 5th and 15th days after weaning respectively. H19 was highly expressed in the fetus (1), during puberty (4), particularly in the terminal-end-bud (arrowhead) and in acini during pregnancy (5). This expression was reduced in all other stages and null during lactation in lobulo-alveolar structures (6). Magni®cation in rows 1, 2 and in I-3 is de®ned by the bar in I-3=275 mm. Magni®cation in other panels (rows 4 ± 8, II-3 and III-3) is de®ned by the bar in I-4=120 mm ubiquitous expression of H19 within primary mammary buds, and also in adjacent tissues (Figure 1 , row 1). At birth, the H19 gene was repressed in most tissues, including in the mammary gland where H19 RNA quantity was dramatically reduced in epithelial and mesenchymal cells (Figure 1, row 2 ). This pattern of expression continued until puberty (Figure 1 , row 3, a 25-day-old female). During puberty, beginning at the 5th week, the mammary epithelium grew extensively and rami®ed throughout the mammary fat pad. This growth was correlated with an increase of H19 gene expression, especially in newly formed terminal-endbuds, whereas the activity of the gene remained unchanged in mesenchymal cells (Figure 1 , row 4, a 35-day-old female). In mature virgin mice, the arrest of ductal development was concomitant with a decrease of H19 RNA synthesis, which reached basal level observed before puberty (data identical to that observed in Figure 1, row 3) . In pregnant mice, the development of lobulo-alveolar structures was accompanied with a very high expression of H19 in the epithelial cells that form the acini, whereas in mesenchymal cells the H19 expression rate did not vary ( Figure 1 , row 5). After parturition, H19 RNA synthesis rapidly decreased and the transcripts became almost undetectable during lactation (Figure 1 , row 6). After weaning, H19 expression increased once more, throughout the involution phases, up to the prepregnancy level (Figure 1 , rows 7 and 8, 5th and 15th days after weaning respectively). At the onset of involution, we noticed an intense H19 signal in some epithelial cells forming clusters. Table 1 summarizes the modulation of the H19 gene expression paralleled with the plasma levels of some steroid hormones in rodents. These observations led us to propose the hypothesis of a control of the H19 gene transcription by steroid hormones during the dierent stages of the mammary gland development after birth and during the various physiological states of the adult female.
H19 gene expression during mouse estrus cycle
To test the action of steroid hormones on H19 gene expression, we determined by ISH H19 RNA quantities in the mammary gland and uterus at each stage of the estrus cycle.
In the mammary gland of mature virgin mice, few signi®cant variations in H19 RNA synthesis were observed during the estrus cycle (Figure 2 ) and the H19 gene expression level remained almost constant. However, in metestrus, the H19 level appeared higher than in other stages ( Figure 2 , row 2). In contrast, in the uterus, it was quite obvious that the H19 gene activity, which was detected in the endometrial stroma and in myometrium but not in luminal and glandular epithelium, varied enormously during the estrus cycle ( Figure 3 ). The H19 transcripts were only localized in some clustered cells. The large variations of H19 gene (1980); (2) Dalle et al. (1978) ; (3) Sanyal (1978) ; (4) Rhoda et al. (1984) ; (5) Smith et al. (1975) ; (6) McCormack and Greenwald (1974) ; (7) Chatelain et al. (1989) ; (8) Lesage et al. (1996) ; (9) expression were correlated with the morphological alterations of the endometrium. A moderate expression of H19 was found in stromal cells and the myometrium during the proestrus ( Figure 3 , row 4) and the level of H19 transcription increased gradually during the proliferative phase until ovulation (estrus, Figure 3 , row 1). After the latter, H19 RNA synthesis remained high during the early secretory phase (metestrus, Figure 3 , row 2), whereas during the late secretory phase it was dramatically reduced (diestrus, Figure 3 , row 3). Then, variations of H19 gene expression in the uterus during the estrus cycle could be related to the actions of steroid hormones on this organ.
Eects of steroid hormones on the H19 gene expression in both ovariectomized and adrenalectomized animals
To investigate more precisely the role of steroid hormones on H19 gene expression, we performed an in vivo study using animals with complete hormonal depletion after surgical castration and adrenalectomy, followed by steroid replacement. Mature virgin mice were ovariectomized, adrenalectomized and then treated with 17-b-estradiol (E2), progesterone (P) and corticosterone (B), either alone or in combination of two or three molecules. Mammary gland and uterus were collected and prepared for ISH; in parallel, rates of circulating hormones were measured by radioimmuno assay (Table 2 ). These hormonal rates in plasma were compatible with the injected doses. Table  2 shows the eect of the dierent treatments on uterus weight and Figure 4 reports correlated variations in the morphology of the uterus. In operated mice injected with the solvent only, the hormonal depletion led to a regression of the uterus (compare Figure 4A with B). E2 provoked a high increase in the weight of the uterus (Table 2 and Figure 4C ), re¯ecting a proliferative activity of this hormone ( Figure 5 , column I). P led to an increase of uterus weight, which was weaker than that induced by E2. A treatment with B alone or in combination with E2 and P restored the normal weight of the uterus (Table 2) . These results are consistent with our knowledge about steroid action on the uterus and validate our experiments. In mammary glands, no H19 RNA synthesis was detectable in the animals which were treated dierently (data not shown). In addition, the hormonal treatments seemed to have few eects on mammary gland morphology. On the contrary, in the uterus, all treatments dramatically aected the development of this organ ( Figure 5, column I) . These morphological and probably physiological changes were accompanied with obvious modulations of the H19 expression. In the uterus of sham-operated mice treated with solvent only, no signi®cant dierence in H19 labeling was observed compared with that reported for nonoperated animals ( Figure 3 ). Eventual individual variations of labeling in these mice could be the consequence of steroid modulations during the estrus cycle as it has been reported above (Figure 3) . The hormonal depletion after the mentioned ablations led to an important repression of H19 gene ( Figure 5 , row 1). The normal pattern of H19 gene expression was Figure 2 H19 gene expression in mammary gland of mature virgin mice during the estrus cycle. I: Hoechst staining. II: in situ hybridization with an antisense H19 riboprobe. 1 ± 4: mouse mammary gland during estrus, metestrus, diestrus and proestrus respectively. H19 expression was very weak in all stages. Nevertheless, H19 RNA synthesis increased very slightly during the metestrus (2). Magni®cation is de®ned by the bar in I-1=160 mm Figure 5 , row 2), but the labeling was weaker than that observed after the E2 treatment alone. Injections of P alone were not able to restore the normal H19 RNA synthesis ( Figure 5 , row 4) and even, in combination with E2 or E2+B, this hormone inhibited, at the dose used, the H19 gene expression ( Figure 5 , rows 5 and 6 respectively).
In vitro study of steroid regulation of the H19 gene expression
To show that steroid hormones could up-and downregulate H19 expression with respectively 17-b-estradiol and progesterone, we performed in vitro experiments.
For this purpose, we ®rst analysed by Northern-blot the H19 RNA synthesis in a human hormone-sensitive mammary epithelial cell line, MCF-7. A weak H19 expression was observed in these cells cultured in normal medium ( Figure 6 , lane 2). This signal seemed slightly reduced when serum-free medium was used ( Figure 6 III: in situ hybridization with an antisense H19 riboprobe. 1 ± 4: mouse uterus during estrus, metestrus, diestrus and proestrus respectively. H19 was expressed in the stroma (arrow) and in the myometrium (double arrows), but not in luminal and glandular epithelium (arrow-head) (metestrus, 2). H19 expression levels were high in estrus and metestrus (1 and 2), weaker in proestrus (4) and the weakest in diestrus (3). These modulations were linked to major morphological changes in the uterus during the estrus cycle (I). Magni®cation in column I is de®ned by the bar in I-1=350 mm. Magni®cation in columns II and III is de®ned by the bar in II-1=160 mm Cotransfection experiments were performed in MCF-7 and in HBL-100 cells: H19 promoter coupled with the luciferase gene was cotransfected with wildtype estrogen receptor (WT ERa) or with wild-type progesterone receptor (WT PR-A) constructs. In normal medium, WT ERa induced a sixfold or a fourfold increase of H19 gene activity in MCF-7 and HBL-100 respectively (Figure 7a) . On the contrary, WT PR-A had no eect on the H19 promoter ( Figure  7a ). Cotransfection of both receptors in MCF-7 attenuated the up-regulation provided by ERa alone, but this counteracting eect of PR-A was not observed in HBL-100 ( Figure 7a ). As MCF-7 and HBL-100 cells contain endogenous estrogen receptors, we then performed other experiments in ER-free human mammary cells . Luciferase activities con®rmed the up-regulation of the H19 promoter by WT ERa and indicated a down-regulation of WT PR-A on this promoter (Figure 7b) . Interestingly, the antagonis- Figure 5 H19 gene expression in mouse uterus after hormonal treatment. I: histological coloration. II: Hoechst staining. III: in situ hybridization with an antisense H19 riboprobe. 1 ± 4: uterus of OVX and ADX mice and treated with solvent, corticosterone (B), 17-b-estradiol (E2) and progesterone (P) respectively. 5: uterus of operated animals treated with E2 and P. 6: uterus of operated animals treated with B, E2 and P. H19 gene expression was reduced after operation (compare row 1 with Figure 3) . E2, and to a lesser extent B, restored the H19 RNA synthesis in stroma and myometrium (rows 3 and 2 respectively). P had no eect on this synthesis when it was administered alone (4), and it inhibited the action of E2 and B (5 and 6). Magni®cation in column I is de®ned by the bar in I-1=350 mm. Magni®cation in column II and III is de®ned by the bar in II-1=160 mm tic actions of WT ERa and WT PR-A described in MCF-7 were as well observed in BT-20 cells (Figure 7a and b).
To gain more insight into the positive regulation of the H19 promoter by E2 and WT ERa, we performed other experiments in MCF-7 cells by using dierent ERa mutants in the presence or in the absence of hormonal stimulation (Figure 7c ). One set of mutants (ER1-530, ER L540Q, ER S554fs) contained alterations into the E domain, which includes the ligand ®xation, the dimerization and the ligand-dependent transactivation domains, and another set of constructs (ER 63, ER 142, ER 182) were mutated into the AF1 domain, the ligand-independent transactivation sequence. In estrogen-free medium, transfection of WT ERa provoked a 2.5-fold increase in H19 promoter activity, and E2 addition further enhanced this positive regulation, about 3.5-fold (compare H19-Luc and H19-Luc+WT ER in Figure 7c , respectively). In estrogenfree medium, two mutated versions of the E domain (ER L540Q and ER S554fs) led to an increase in H19 promoter activity, but weaker than that induced by WT ERa. After E2 addition, these mutants behaved similarly to the WT receptor in up-regulating the H19 promoter. The ER1-530 mutant had no eect on the promoter and the enhancing eect brought by E2 was smaller when compared to others (Figure 7c ). As illustrated for ER 142 mutant in Figure 7c , the three AF-1 ERa mutants down-regulated the H19 promoter, whether or not E2 was present in the medium (50 and 33% inhibition, respectively). This down-regulation of the H19 promoter by AF-1 mutants was con®rmed by the eect of the two other altered AF-1 constructs: 45 and 30% inhibition with ER 63, 60 and 50% inhibition with ER 182, whether or not E2 was added to the culture medium, respectively.
Discussion
Several data have been reported on the status of H19 gene expression in carcinomas and cancerous cell lines, but little is known about its expression in healthy tissues and the factors implicated in this regulation. In a previous study, we demonstrated that in breast adenocarcinomas the H19 gene overexpression was signi®cantly correlated with the presence of estrogen and progesterone receptors . To determine more precisely the eects of steroid hormones on the H19 gene expression, we observed the modulations of the H19 RNA synthesis in two hormone-sensitive organs (mammary gland and uterus) at dierent normal stages of life in mice; then we went further into the details of the role of steroid hormones in ovariectomized and adrenalectomized animals in hormone replacement experiments; ®nally we analysed the control of steroid hormones, via their receptors, on the H19 promoter.
ISH results showed that during the genesis of the mammary gland, H19 gene expression depends on the stage of development. In the fetus, H19 gene activity is high in the mammary bud and in adjacent tissues. This result is in agreement with previous studies which demonstrated that most of fetal tissues (except the thymus) strongly expressed this gene Hemberger et al., 1998) . As the fetal mammary gland development is not underlying with hormonal stimulation (Topper and Freeman, 1980) , we can speculate that during fetal life, the strong H19 expression is independent of hormonal actions. At birth, the H19 RNA synthesis is strongly attenuated and although this repression is general, its rate depends on the organ. This repression is not complete in the mammary cord ( Figure 1) and a basal transcription level persists in the adult, as previously described (Douc-Rasy et al., 1993; Dugimont et al., 1995; Adriaenssens et al., 1998) . This pattern of expression remains all along the prepubertal development and during this stage the mammary gland growth is isometric and no morphological or functional variations occur. At the time of sexual maturation, the terminal extremity of the mammary ducts grows up again and forms the terminal-end-buds which then invade the fat pad; simultaneously the branching degree of the ducts increases. All these phenomena need proliferation, migration and dierentiation of the epithelial cells and are correlated with a high expression of the H19 gene, especially in terminalend-buds (Figure 1, row 4) . These results suggest that the H19 gene could be implicated in one or more of these mechanisms. In mature virgin mice, after the arrest of ductal growth, the H19 gene expression becomes weak and remains constant. This observation is discussed further on. In pregnant mice, the mammary ducts dierentiate into lobulo-alveolar structures and the adipocyte part is dramatically reduced; at this stage the H19 gene is strongly expressed (Figure 1, row 5 ). It must be underlined that high rates of H19 RNA synthesis in the mammary gland occurred at puberty and pregnancy, which are the two preferential stages in which steroid hormones exhibit a high activity. During lactation, the lobular system dierentiates to form acini producing milk. At this stage, the mammary gland reaches its complete stage of dierentiation ensuring a nutritive function. All along this stage, the H19 gene expression is completely repressed in all mammary components. Thus, it seems that H19 is not associated with the terminal dierentiation of epithelial cells, which arises A weak H19 signal was detected in MCF-7 in the presence of serum. This level was very slightly diminished in serum-free medium. H19 gene expression was obviously increased when cells were stimulated by 17-b-estradiol and tamoxifen signi®cantly reduced this stimulation Steroid hormones modulate H19 gene expression E Adriaenssens et al during lactation. At the time of involution, a disorganization of the epithelial lobulo-alveolar structures occurs and the mammary gland recovers its prepregnancy status; these phenomena are accompanied with a return to basal level of the H19 gene expression. It is well known that estrogens stimulate the ductal development during puberty, whereas progesterone, in combination with estrogens, regulates the lobuloalveolar development during pregnancy (Nandi, 1958; Haslam and Shyamala, 1980; McCormack and Greenwald, 1974) . Thus, the high expression of H19, particularly during these two stages, argues in favor of a role of H19 gene in the mammary gland development and suggests that this developmental regulation is under endocrine control.
To ascertain this hypothesis, we studied by ISH the H19 gene expression in mammary gland and uterus during the estrus cycle. In the mammary gland of mature virgin mice, no real signi®cant variations of H19 gene expression were observed at the various stages of the estrus cycle, except a weak increase in labeling during the metestrus. This absence of a large variation can be correlated with the absence of high morphological repair during the estrus cycle in this organ. It appears then that H19 is highly expressed in the mammary gland only when canal morphogenesis occurred, but its expression remains rather weak and constant during periods of comparative rest. Consequently, in the mammary gland the H19 RNA synthesis seems to be sensitive to high doses of hormones (for instance during puberty or pregnancy), but not to more moderate variations of hormone concentrations (in the estrus cycle). We demonstrated on the contrary that in the uterus H19 labeling varied during the estrus cycle. During the proliferative phase (proestrus, estrus) and early secretory phase (metestrus), the H19 RNA synthesis increased gradually, whereas in diestrus (late secretory phase) the H19 labeling was the weakest. In view of these results, we hypothesized that the cyclic changes of the H19 expression can be assigned to hormonal variations. . E2 stimulated about three times the H19 promoter (H19-Luc control). -WT ERa increased three to four times the luciferase activity (H19-Luc+WT ERa). In absence of E2, two E mutants (ER L540Q, ER S554fs) showed a signi®cant activation of the H19 promoter, but the third one (ER1-530) had no eect. -When E2 was added to the culture medium, WT ERa and the three E mutants exhibited an obvious positive activity on the H19 promoter. Only ER1-530 seemed to be less ecient to induce an up-regulation on the studied promoter. These up-regulations by ERa mutated into the E domain suggested a ligand-independent action of ERa on the H19 promoter. Interestingly, this property was con®rmed by using an AF-1 mutant (ER 142) showing 33% and 50% inhibition in absence or in presence of E2, respectively Furthermore, the discrepancies observed between the responses of the H19 gene in the mammary tissues and those in the uterine tissues during the estrus cycle could account for the higher sensitivity of the uterus to hormone variations, compared to the mammary gland. Otherwise, some of our results obtained in mouse dier from those observed by Ariel et al. (1997b) in humans. Indeed, in humans, the H19 labeling is ubiquitous in the stromal component of the uterus, whereas in the mouse only some cells forming clusters express H19 (Figures 3 and 5) . In addition, the H19 activity in myometrium seems to be speci®c to the mouse model. Likewise, the modulations of H19 gene expression in the murine uterus are not in agreement with that reported in the human uterus (Ariel et al., 1997b) : in human endometrium, a peak of H19 expression arises at the late secretory phase and the weakest H19 RNA synthesis appears at the beginning of this phase; on the contrary, in the murine homolog tissue, the high and low levels of H19 activity are observed at the early and late secretory phases respectively. These discrepancies can be explained by the dierences between the human and the mouse sexual cycle. Indeed, the murine estrus cycle diers considerably from the human menstrual cycle, in particular, its short duration (4 days) does not suciently prepare the endometrium for the nesting of the blastocysts. The dierentiation of the uterus appears to be un®nished in the mouse at the end of the cycle, whereas in humans, the uterus is ready to accept the embryo at the end of the luteinic phase. Therefore, the H19 expression patterns in mouse and human uterus seem to be species speci®c.
To determine which steroid hormones could be implicated in the regulation of the H19 gene, we performed hormonal replacements in ovariectomized and adrenalectomized animals. In the mammary gland, no H19 RNA synthesis was observed regardless of the injected hormones (17-b-estradiol: E2, progesterone: P, corticosterone: B). The same results were obtained in prepubescent mice (24-day-old animals) that were ovariectomized and adrenalectomized and similarly treated with hormones (data not shown). Several reasons could explain these results in the mammary gland: either arti®cial hormone treatments were not able to reproduce the appropriate normal conditions arising during puberty or pregnancy, or the hormonal dosage must be very accurate to induce an obvious upregulation of the H19 gene, or hormones may act in synergy with other mediators which are absent from our injection experiments. These statements justify further investigations on H19 RNA synthesis in mammary cells and according to above data we can not exclude that in mammary gland the H19 gene expression is directly in¯uenced by steroid hormones. In other respects, injected hormones provoked modulations of H19 gene expression in the uterus, an a priori more sensitive organ. The hormonal depletion led to the absence of H19 labeling in this organ. E2 and B were responsible for an up-regulation of H19, whereas P repressed the gene. Compared to the normal situation, the injection of E2 or B provoked an increase in the labeling of cells gathered in clusters, but not a recruitment of more cells expressing the gene. Consequently, H19 could be used as a marker of hormone-sensitive cells in the uterus of mice. It is interesting to notice that when the mice were treated with B or E2, dramatic morphological changes and dierentiation in the uterus were accompanied with a recovery of H19 gene expression, whereas when mice were treated with P, few changes occurred and H19 gene expression remained null. In addition, these data can explain the modulations of H19 RNA synthesis observed in the estrus cycle. Indeed during the cycle, the H19 expression is under the control of two opposite actions: an up-regulation by E2 and a down-regulation by P. Likewise, we noticed that the high H19 expression (during estrus and metestrus) did not coincide exactly with the peak of estrogen (proestrus-estrus). This discrepancy can be explained by the action of other factors modulating hormonal actions themselves, by the delay required for the synthesis of H19 RNA after hormonal stimulations, or by the half-life of the RNA. If we hypothesize that E2 and P have similar actions during the development of the mammary gland (at high doses) and in uterus, we can explain the high H19 expression during puberty and pregnancy by a high estrogen stimulation, in spite of the presence of progesterone. Development of the mammary gland and the uterus involve proliferation, then dierentiation of cells. These two mechanisms are usually associated, and it is commonly admitted that estrogens drive rather cell proliferation, whereas progesterone provokes cell dierentiation (Haslam, 1987) . Although our results do not confer an accurate function to the H19 gene, the up-regulation by estrogens and the down-regulation by progesterone suggest an implication of H19 in some proliferation processes, at least in the uterus where the hormonal control of H19 gene expression is unambiguous. Nevertheless, using antibodies raised against Ki-67, a cell cycle marker protein, we have determined that H19 gene expression is not correlated with this cell cycle marker (data not shown). Then, relationships between H19 gene expression and proliferation processes remain a matter of debate.
Finally, we report that E2 stimulated the H19 RNA synthesis in MCF-7, a hormone-sensitive mammary epithelial cell line, whereas tamoxifen signi®cantly reduced this estrogen-induced synthesis. Consequently, we performed cotransfection assays in hormonesensitive cells (MCF-7 and HBL-100) and in hormone-insensitive cells (BT-20), and we further investigated the steroid hormones and their speci®c nuclear receptors action on an ectopic H19 promoter. In the three lines, we demonstrated that transfection of wildtype estrogen receptor (WT ERa) was followed by a clear increase in the H19 promoter activity. Experiments involving the progesterone receptor (PR-A) indicated a down-regulation of the promoter in BT-20 and no eect in MCF-7 and HBL-100 cells. These results are in agreement with the up-and the downregulation of H19 observed after E2 and P in vivo systemic stimulations, respectively. Furthermore, the obvious impeding eect of WT PR-A on the H19 promoter stimulation mediated by WT ERa observed in cotransfected MCF-7 and BT-20 was not found in HBL-100. This discrepancy results most likely from dierences in the cell type and the promoter context used for analysis and in the relative expression of transcriptional machinery (co-factors and co-repressors). Results obtained in MCF-7 and in BT-20 cells (in relation with in vivo data) are in agreement with the general opposing action of estrogens and progestins (Kraus et al., 1995) , but this antagonism seems to be less clear in HBL-100 cells. In fact, Kraus et al. (1995) and more recently Giangrande et al. (1997) mentioned that the molecular mechanism(s) whereby progestins antagonize estrogen actions has not been clearly elucidated.
We went thoroughly into the E2-ERa control of the H19 promoter with cotransfections of various mutated ERa constructs (alterations into the E or AF-1 domains of ERa). In the absence of E2 stimulation, WT ERa as the E domain mutated forms (except ER1-530) induced an increase in H19 promoter activity, but these altered ERa were less eective. These results are in favor of a ligand-independent up-regulation of the H19 promoter, but we cannot exclude that these mutants are not completely inactivated. Indeed, in the altered versions used, the mutations map within the E domain of the nuclear receptor, sequence which contains the ligand ®xation, the dimerization and the hormone-dependent transactivating region (AF-2). Consequently, it is conceivable that these mutations lead to an actual hormone-independent transactivation. On the contrary, when cotransfected cells were stimulated by E2, WT and E mutant ERa transactivated the H19 promoter in the same manner. Only ER1-530 seems to be less eective. These similar responses can be explained by a cooperation between exogenous ERa (WT or mutated versions) and the bulk of endogenous ERa, which is present in MCF-7 cells. In fact, the loss of dominant negative activity of the three E mutants can be explained by a cross-talk between AF-1/AF-2 domains and/or by an incomplete inactivation of these mutants (see also Lahooti et al., 1995 and Ince et al., 1995) . In other respects, we can rule out that this E2-independent eect was due to an imperfect clearance of E2 by performing a bona ®de E2-dependent o/on induction of a reporter gene under the control of an estrogen response element (ERE-Luc) transfected alone or with WT ERa (data not shown).
Finally, the actual hormone-independent transcriptional ERa activity on the H19 promoter has been demonstrated by using ERa mutants altered in their AF-1 transactivation domain. We bring herein evidence which clearly indicates that the studied promoter is repressed by these mutants in absence or in presence of E2 in the culture medium. These inhibiting properties stress a probable negative transdominant eect on endogenous receptor action.
The discrepancy between luciferase activities in MCF-7 cells after cotransfection with ERa in normal medium with 10% serum (Figure 7a , H19-Luc +WT ERa versus H19-Luc, sixfold activation) and in a serum-free medium plus 17-b-estradiol (Figure 7c , H19-Luc+WT ERa+ E2 versus H19-Luc +E2, threefold activation) suggests the presence in serum of coactivators responsible for an increase in H19 gene activation. It is known that estrogens are required for converting the ERa to a transcriptionally active form able to stimulate many genes (Kraus et al., 1995) . Furthermore, numerous data indicate that nuclear receptors, in particular the estrogen receptor, can be activated in the absence of their speci®c ligand (Weigel and Zhang, 1998; El Tanani and Green, 1997; Lee and Yee, 1995) . In this case, other mediators seem to be necessary to activate the nuclear receptor (dopamine, antiestrogen, IGFs, EGF and cAMP). These factors provoke a conformational change in the receptor which becomes able to transactivate targeted genes. Although no component responsible for this phenomenon has been identi®ed, we have demonstrated in vitro that H19 gene can be activated by ERa in a cognate-ligandindependent manner. It is clear that the latter is not an unique pathway because in the whole animal as well as in a cell line (MCF-7) studies have shown a response of H19 gene to estradiol. It seems then that H19 gene could be activated by the estrogen receptor in both the ligand-independent and ligand-dependent manners. In addition, our results can explain several observations of H19 gene regulation reported in dierent models: as PKA and IGFs increase the H19 gene expression (Voutilainen et al., 1994) , it is conceivable that these factors act through the estrogen receptors. Finally, even if E mutated ERa involved in our study have been previously described as exhibiting a negative transdominant role on an arti®cial promoter containing canonical estrogen responsive element, ERE, Ince et al., 1995) , we demonstrated that these mutants can transactivate the minimal H19 promoter through their non hormone-sensitive transactivating region. This statement is con®rmed by using AF-1 ERa mutants. Very recently, Hanstein et al. (1999) con®rmed that the N-terminal transactivating region (AF-1) is able to activate transcription in a hormone-independent manner. We can hypothesize that the induction of H19 gene results of an increase of available AF-1 region number, which is able to transactivate the promoter per se or in combination with the bulk of endogenous WT ERa. The H19 promoter is devoid of canonical estrogen responsive elements, but exhibits several consensual or degenerated half-sites. Some studies have shown that the estrogen receptor can bind various direct or inverted repeats of the ERE half-sites (Kato et al., 1995; Aumais et al., 1996) , so ERa could act on H19 promoter by a direct manner too.
In conclusion, this study demonstrates that steroid hormones regulate H19 gene expression. It is obvious that in the uterus, 17-b-estradiol enhances the H19 RNA synthesis, whereas progesterone represses it. Both these actions, experimentally demonstrated in vivo, explain the modulations observed during the estrus cycle. It appears that H19 is highly expressed when an organ (mammary gland or uterus) undergoes an extensive remodeling of its morphology and/or physiological state. It seems that alterations of the mammary gland are too weak during the estrus cycle to allow an overexpression of the H19 gene at a peculiar stage. However, an actual steroid regulation of the gene must exist in the mammary gland as modulations of H19 RNA synthesis have been observed all throughout the normal physiological stages of life of female mice. Finally, in vitro experiments con®rmed that estradiol and progesterone exerted opposite roles on the H19 promoter. Nevertheless, these experiments do not distinguish between a direct or an indirect action of steroid hormones on H19 gene expression since these hormones can transactivate transcription factor gene expression which then regulates the H19 gene. The dierences between in vivo and in vitro manipulations can explain the absence of an estrogenic activation in the mammary gland in ovariectomized and adrenalectomized animals after hormonal replacements, whereas in mammary cultured cells this activation is obvious. Indeed, we can suppose that in in vitro experiments some cofactors are missing, which however are present in vivo. Likewise, the vector used in the cotransfection experiments contained only the minimal H19 promoter, but a cis-regulating region, missing in vitro, may be implicated in vivo. The cooperation of the 5' upstream and the 3' downstream regions of the mouse H19 gene was previously described by Yoo-Warren et al., (1988) . More recently, the implication of a cis-acting region in the H19 activation was demonstrated since the upregulation of human H19 promoter by retinoic acid is dependent upon the 3' downstream domain (Kopf et al., 1998) . Finally, although evidences obtained either without hormonal stimulation or with mutant receptors substantiate a partially hormono-independent action of ERa, in vivo and in vitro experiments clearly demonstrate the regulation of H19 gene by steroid hormones.
Materials and methods
Animals in normal physiological states
The mammary glands (inguinal pairs 4 and 5) of Swiss 3T3 mice were collected at the following stages: embryonic life (E14.5), at birth (D0), before, during and after puberty (D25, D35 and mature virgin animals, respectively), during pregnancy (14th day), lactation (10th day after parturition), and involution (5th and 15th days after weaning).
During the estrus cycle, mammary glands and uterus were collected on mature virgin mice. Each stage of the cycle (estrus, metestrus, diestrus and proestrus) was determined by vaginal smears from 12 week old mice.
Hormone-treated animals
Twelve-week-old mice were ovariectomized (OVX) and adrenalectomized (ADX) or sham-operated under ether anesthesia. One week after surgery, we proceeded to the following treatments: subcutaneous injection of 17-b-estradiol (20 mg/kg/day), or progesterone (1 mg/kg/day), or both in 10 ml of sesame oil as solvent. In parallel, some animals were treated with corticosterone (0.3 mg/kg/day) dissolved in 10 ml of the following solvent: absolute ethanol/0.9% NaCl (1 : 49 v/v). The latter hormone was injected either alone or in combination with estradiol and progesterone. Two control experiments were performed by injection of 10 ml of solvent in operated or sham-operated mice. After 2 weeks of treatment, inguinal mammary glands and uterus were collected on sacri®ced animals. All steroids were purchased from Sigma.
Quantitative determination of circulating hormones
Corticosterone and estradiol concentrations in plasma were measured by radio-immuno assay as previously described (Bernet et al., 1994; Lesage et al., 1996, respectively) . Quantitative determination of progesterone in the plasma has been performed by a radio-immuno assay kit (PROG-CTRIA) purchased from Cis Bio International (Gif-surYvette, France). The polyclonal anti-progesterone antibody presents the following cross-reactions at B/BO=0.5: progesterone 100, deoxycorticosterone 6.2, 20 a-dihydroprogesterone 2.2, 6 b-dihydroprogesterone 2.1, 16 ahydroxyprogesterone 1.6, 5 b-dihydroprogesterone 0.7, 17 bhydroxyprogesterone 0.5, testosterone 0.09, cortisol, estradiol and pregnenolone50.02. The variability was 3.5% (intraassay) and 4.5% (inter-assay).
Cell cultures
Three human mammary epithelial cells, MCF-7, HBL-100 and BT-20 were obtained from ATCC (USA). MCF-7 and HBL-100 are hormone-sensitive lines, but BT-20 are a hormone-insensitive one (indications from ATCC references and experiments of two groups from our laboratory, Peyrat et al., 1991; El Yazidi et al., 1998) . They were cultured in MEM supplemented with 10% Fetal Calf Serum (FCS), 2 mM glutamine, 100 U-100 mg/ml penicillin-streptomycin, 1% non essential amino acids (all purchased from Eurobio), and 5 mg/ml insulin (Endopancrine, Organon). Cells were plated in 100 mm dishes and were grown to subcon¯uent stages.
In some experiments the culture medium was replaced by phenol-red free medium (Eurobio), supplemented with bovine serum albumin (BSA fraction V) at 2 g/l, penicillinstreptomycin, glutamine, non essential amino acids, insulin (40 U/ml) and human transferrin (10 mg/l). After 48 h, cells were treated with hormones for 24 h and harvested.
Fixation, embedding and section of organs
Mammary glands and uterus were ®xed overnight at 48C in 4% paraformaldehyde-PBS, rinsed in PBS, dehydrated through increasing ethanol concentrations, embedded in paran and serially cut. Seven mm-sections were transferred to`SuperFrost plus' coated slides (Polylabo), incubated at 378C 1 week and stored at 48C until use.
Histological colorations
Picro-indigo-carmin (PIC) or hemalun-phloxine-safran (HPS) colorations were performed on one section of each sample in order to determine histological structures and to precisely localize the interesting areas for in situ hybridization.
In situ hybridization (ISH)
ISH was performed as previously described by QueÂ va et al. (1992) . Labeled probes were obtained as follows: antisense and sense 35 S-CTP RNA probes were transcribed by SP6 polymerase from a 1.3 kb StuI fragment of the human H19 cDNA cloned at a SmaI site into pSP64 vector (Promega). Before in vitro transcription, the vector was linearized by HindIII. The 77%-nucleotide conservation between murine and human H19 genes accounts for the cross-hybridization between in situ murine H19 RNA and the human H19 probe.
After dipping in a nuclear-track emulsion (Kodak NTB2), the slides were exposed for 3 weeks at 48C before development. They were then stained by the intercalating dye Hoechst 33258, mounted in Glycergel (Dako) and observed under a double illumination using an Olympus BH2 photo-microscope, with epi¯uorescence for Hoechst staining and a dark-®eld condenser for silver grain detection.
Northern blot analysis
Total RNAs were prepared from MCF-7 cells by the guanidium isothiocyanate-CsCl gradient method (Sambrook et al., 1989) . RNAs (20 mg) were separated on a 1.2% agarose/formaldehyde gel and transferred overnight onto a nitrocellulose membrane (Hybond-C-extra, Amersham). The membrane was placed at 808C for 2 h and hybridized at 428C with a 32 P-dCTP-labeled random primed cDNA probe (Megaprime Labeling System, Amersham). H19 probe was a PstI fragment (1.2 kb) obtained by digestion of the pSP64 vector mentioned above. A GAPDH (Glyceraldehyde-3'-Phosphate Dehydrogenase) probe was used to quantify the H19 RNA.
Cotransfection experiments
MCF-7, HBL-100 and BT-20 cells were transiently cotransfected with the pGL2 plasmid containing the H19 minimal promoter region (823 bp) associated with the luciferase reporter gene and the pCMV5 plasmid containing a sequence coding for dierent transcripts of the estrogen receptor (ERa) gene: i.e. wild-type (WT ERa), three E domain mutants: a frame-shifted ER (S554fs), a point mutated ER (L540Q) and a truncated ER (ER1-530); three AF-1 domain mutants (ER 63, ER 142 and ER 182) . The a letter precises the ER type used in this study, since a recently discovered receptor, named ER-b, has been cloned and characterized by Kuiper et al. (1996) and Mosselman et al. (1996) . The ERE-Luc was a vector containing an AGGTCA n (3) TGACCT sequence repeated twice up stream the tkLuc. We performed other experiments using a pKSV10 plasmid in which a wild-type (WT) progesterone receptor cDNA was inserted. The A letter indicates the PR-isoform used in transfection experiments; we recall that a PR-B isoform has been described (Ilenchuck and Walters, 1987; Gronemeyer et al., 1991) . Information on pGL2 recombinate vectors can be obtained in Dugimont et al. (1998) . pCMV 5 and pKSV10 recombinate vectors are described in Reese and Katzenellenbogen (1991) and in Guiochon-Mantel et al. (1988) , respectively.
Cotransfections were performed by using FuGENE TM 6 reagent (Boehringer Mannheim, USA): 1.75 mg of H19-luciferase plasmid and 0.35 mg of the tested plasmid were used for the cotransfections of cells plated in a six-well dish. Controls were performed by using empty plasmids. Cells were incubated with reagents 6 h at 378C, then the culture medium was changed. 48 h after transfections, cells were harvested with a reporter lysis buer (Promega, Madison, WI, USA). Luc assay was performed by using a luciferase assay system (Promega kit) and Luc activities were measured by a lumat LB 9501 (Berthold). Luc activities were normalized with total protein concentrations determined by densitometry (DU R 64 spectrophotometer, Beckman) at 595 nm wavelength.
